Establishment Labs (NASDAQ:ESTA) Posts Earnings Results, Misses Expectations By $0.34 EPS

Establishment Labs (NASDAQ:ESTA - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34), Zacks reports. The business had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA traded up $0.34 during trading on Friday, reaching $42.87. 653,835 shares of the stock traded hands, compared to its average volume of 685,039. The company has a 50-day moving average of $37.50 and a 200-day moving average of $41.34. Establishment Labs has a 52-week low of $28.16 and a 52-week high of $60.12. The stock has a market capitalization of $1.20 billion, a P/E ratio of -16.62 and a beta of 1.12. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29.

Analysts Set New Price Targets

Separately, Stephens restated an "overweight" rating and set a $52.00 price target on shares of Establishment Labs in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $57.40.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.